Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer,The New England Journal of Medicine

当前位置： X-MOL 学术 › N. Engl. J. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
The New England Journal of Medicine ( IF 96.2 ) Pub Date : 2022-06-05 , DOI: 10.1056/nejmoa2203690
Shanu Modi ₁ , William Jacot ₁ , Toshinari Yamashita ₁ , Joohyuk Sohn ₁ , Maria Vidal ₁ , Eriko Tokunaga ₁ , Junji Tsurutani ₁ , Naoto T Ueno ₁ , Aleix Prat ₁ , Yee Soo Chae ₁ , Keun Seok Lee ₁ , Naoki Niikura ₁ , Yeon Hee Park ₁ , Binghe Xu ₁ , Xiaojia Wang ₁ , Miguel Gil-Gil ₁ , Wei Li ₁ , Jean-Yves Pierga ₁ , Seock-Ah Im ₁ , Halle C F Moore ₁ , Hope S Rugo ₁ , Rinat Yerushalmi ₁ , Flora Zagouri ₁ , Andrea Gombos ₁ , Sung-Bae Kim ₁ , Qiang Liu ₁ , Ting Luo ₁ , Cristina Saura ₁ , Peter Schmid ₁ , Tao Sun ₁ , Dhiraj Gambhire ₁ , Lotus Yung ₁ , Yibin Wang ₁ , Jasmeet Singh ₁ , Patrik Vitazka ₁ , Gerold Meinhardt ₁ , Nadia Harbeck ₁ , David A Cameron ₁ ,

Affiliation

From the Memorial Sloan Kettering Cancer Center, New York (S.M.); Institut du Cancer de Montpellier, Université Montpellier, INSERM Unité 1194, Montpellier (W.J.), and Institut Curie, Université Paris Cité, Paris (J.-Y.P.) - both in France; Kanagawa Cancer Center, Yokohama (T.Y.), Kyushu Cancer Center, National Hospital Organization, Fukuoka (E.T.), Showa University Hospital, Tokyo (J.T.), and Tokai University School of Medicine, Isehara-shi (N.N.) - all in Japan; Yonsei Cancer Center, Yonsei University Health System (J. Sohn), Samsung Medical Center (Y.H.P.), Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University (S.-A.I.), and Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Seoul, Kyungpook National University Chilgok Hospital, Daegu (Y.S.C.), and the National Cancer Center, Goyang-si (K.S.L.) - all in South Korea; the Department of Medical Oncology, Hospital Clínic de Barcelona (M.V., A.P.), Translational Genomics and Targeted Therapies in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (A.P.), the Department of Medicine, University of Barcelona (A.P.), the Breast Cancer Unit, Institute of Oncology (IOB)-Quirón Salud (A.P.), Institut Catala d'Oncologia l'Hospitalet-Hospital Duran i Reynals (M.G.-G.), and Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (C.S.) - all in Barcelona; the University of Texas M.D. Anderson Cancer Center, Houston (N.T.U.); Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (B.X.), Zhejiang Cancer Hospital, Hangzhou (X.W.), the First Hospital of Jilin University, Changchun (W.L.), Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou (Q.L.), West China Hospital, Sichuan University, Chengdu (T.L.), and Liaoning Cancer Hospital and Institute, Shenyang (T.S.) - all in China; the Cleveland Clinic Foundation, Cleveland (H.C.F.M.); the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco (H.S.R.); Rabin Medical Center, Petah Tikva, Tel Aviv University, Tel Aviv, Israel (R.Y.); Alexandra Regional General Hospital, Athens (F.Z.); Institut Jules Bordet, Brussels (A.G.); Queen Mary University of London, London (P.S.), and Edinburgh Cancer Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh (D.A.C.) - both in the United Kingdom; Daiichi Sankyo, Basking Ridge, NJ (D.G., L.Y., Y.W., J. Singh, P.V., G.M.); and the Breast Center, Department of Obstetrics and Gynecology, and Comprehensive Cancer Center Munich, Ludwig Maximilian University Hospital, Munich, Germany (N.H.).

New England Journal of Medicine, Ahead of Print.

中文翻译：